Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
AUNA
Auna S.A.
AUNA operates hospitals and provides inpatient and outpatient care, i.e., hospital services.
|
$415.71M |
$5.62
+1.81%
|
|
LRMR
Larimar Therapeutics, Inc.
Nomlabofusp is a recombinant fusion protein, i.e., a recombinant protein/enzyme therapeutic.
|
$410.83M |
$4.81
+1.91%
|
|
ENTA
Enanta Pharmaceuticals, Inc.
Enanta is actively developing antiviral small-molecule therapeutics targeting RSV, fitting the Antiviral Small-Molecule Therapeutics theme.
|
$404.37M |
$14.01
-0.39%
|
|
CERS
Cerus Corporation
Cerus' INTERCEPT Blood System is a medical device platform; primary product is a device used in transfusion safety.
|
$399.54M |
$2.08
+4.00%
|
|
NVEC
NVE Corporation
Medical devices & biometrics applications, including implantable sensors and collaboration with Abbott.
|
$398.39M |
$82.60
+3.56%
|
|
IRD
Opus Genetics, Inc.
Core product area: AAV-based gene therapies for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$396.54M |
$5.77
+0.35%
|
|
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
Lead programs are oral small-molecule therapeutics targeting NI&I indications.
|
$394.84M |
$13.54
+1.80%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics' core business is developing allogeneic cell therapy platforms and products (OpRegen, OPC1, ReSonance ANP1).
|
$393.86M |
$1.71
+3.96%
|
|
AURA
Aura Biosciences, Inc.
Aura's lead oncology program bel-sar is a cancer therapy, targeting solid tumors and advancing in Phase 3.
|
$393.22M |
$6.16
-2.69%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
Company operates oncology-focused biotechnology with immunotherapy assets.
|
$389.89M |
$8.61
|
|
ITOS
iTeos Therapeutics, Inc.
iTeos Therapeutics is a biotech company focused on oncology, developing cancer immunotherapies.
|
$388.48M |
$10.15
|
|
NUS
Nu Skin Enterprises, Inc.
The Prysm iO and related wellness devices involve medical/biometric device technology.
|
$385.13M |
$7.90
+3.27%
|
|
DCTH
Delcath Systems, Inc.
Delcath's core offering is a Drug Delivery Platform enabling hepatic delivery of chemotherapy (PHx/HEPZATO KIT) for liver-directed treatment.
|
$383.51M |
$10.88
+0.46%
|
|
BLDE
Blade Air Mobility, Inc.
Blade's Medical segment provides healthcare logistics services including organ transport and related operations.
|
$383.21M |
$4.73
|
|
NAUT
Nautilus Biotechnology, Inc.
The hardware/assay suite functions as diagnostic-type equipment for proteomics analyses.
|
$382.70M |
$3.03
-3.04%
|
|
MNPR
Monopar Therapeutics Inc.
MNPR is pursuing oncology-focused assets (MNPR-101 radiopharmaceuticals) and monoclonal antibody–based therapies, aligning with Biotech - Oncology.
|
$380.87M |
$56.59
-8.33%
|
|
ZURA
Zura Bio Limited
Zura Bio develops immunology therapeutics for autoimmune and inflammatory diseases (Immunology Therapeutics).
|
$377.79M |
$5.81
+1.75%
|
|
PBYI
Puma Biotechnology, Inc.
Direct oncology biotech core product portfolio with Nerlynx and alisertib being cancer therapies.
|
$376.42M |
$7.47
+3.18%
|
|
VIGL
Vigil Neuroscience, Inc.
Direct product: Vigil's lead program iluzanebart is a fully human monoclonal antibody TREM2 agonist, categorizing under Monoclonal Antibody Therapeutics.
|
$375.71M |
$8.05
|
|
XFOR
X4 Pharmaceuticals, Inc.
Company develops therapies targeting rare immune disorders (WHIM syndrome, CN), fitting Biotech - Rare Diseases.
|
$375.10M |
$4.27
+3.14%
|
|
AKBA
Akebia Therapeutics, Inc.
Vafseo (vadadustat) is Akebia's core product, an oral small-molecule therapeutic (HIF-PHI) for CKD anemia, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$372.84M |
$1.41
+4.07%
|
|
EPRX
Eupraxia Pharmaceuticals Inc.
Diffusphere is Eupraxia's proprietary drug-delivery platform enabling localized, extended-release formulation, a core product/technology they directly develop and apply to its pipeline candidates EP-104IAR and EP-104GI.
|
$370.89M |
$6.88
-6.21%
|
|
VMD
Viemed Healthcare, Inc.
Viemed operates as an in-home healthcare provider delivering home health and hospice services.
|
$370.29M |
$9.73
+1.72%
|
|
BCYC
Bicycle Therapeutics plc
Company's core focus is oncology with Bicycle Molecule platform and multiple lead oncology programs.
|
$369.73M |
$5.33
+3.79%
|
|
GNE
Genie Energy Ltd.
Health Insurance: Captive insurance subsidiary offering tailored health insurance products to retail customers.
|
$369.12M |
$13.88
+1.91%
|
|
LENZ
LENZ Therapeutics, Inc.
VIZZ is an aceclidine-based eye drop marketed as an ophthalmic drug for presbyopia.
|
$367.36M |
$12.86
-0.89%
|
|
ALT
Altimmune, Inc.
Pemvidutide is a peptide therapeutic developed by Altimmune (GLP-1/glucagon dual receptor agonist); directly matches the 'Peptide Therapeutics' investable theme.
|
$364.89M |
$3.49
-0.57%
|
|
NMRA
Neumora Therapeutics, Inc. Common Stock
Company focuses on neuropsychiatric drug development, including navacaprant for major depressive disorder, aligning with Neuropsychiatric Drug Development.
|
$359.24M |
$2.15
+7.50%
|
|
IMRX
Immuneering Corporation
Atebimetinib (IMM-1-104) is an oral small-molecule therapeutic in clinical trials.
|
$359.01M |
$5.55
-0.27%
|
|
SOPH
SOPHiA GENETICS S.A.
Liquid Biopsy: MSK-ACCESS application and liquid biopsy analytics integrated into the platform.
|
$358.23M |
$5.28
+3.03%
|
|
PALI
Palisade Bio, Inc.
PALI-2108 is an orally administered small molecule therapeutic, matching the Oral Small Molecule Therapeutics tag.
|
$357.61M |
$2.40
+2.79%
|
|
LAB
Standard BioTools Inc.
SomaScan laboratory testing and advisory services are a core direct offering.
|
$357.61M |
$0.93
+1.01%
|
|
DMAC
DiaMedica Therapeutics Inc.
DMAC's lead DM199 is a peptide/protein-based therapeutic (recombinant KLK1) aimed at treating AIS and PE.
|
$356.73M |
$6.86
+3.55%
|
|
KROS
Keros Therapeutics, Inc.
Duchenne muscular dystrophy (DMD) and associated cytopenias are rare diseases, aligning Keros Therapeutics' focused assets to Rare Diseases.
|
$355.54M |
$11.68
-0.34%
|
Showing page 19 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
